Meddenovo Drug Design has entered a strategic collaboration with Daiichi Sankyo through its Daiichi Sankyo Research Institute Munich.
Building on its expertise in designing novel cyclic peptide structures from scratch, Meddenovo will apply its computational platform, Mexa, to generate and optimize peptide candidates tailored to specific therapeutic targets of interest.

The new project, entitled “AI-Driven Design of pH-Responsive, Functionalizable Cyclic Peptide-Based Drug Candidates for Solid Tumors.” includes two biological targets aimed as oncology therapeutics. The project is structured in two sequential one-year phases. In the first phase, Meddenovo will advance candidate cyclic peptides through comprehensive AI-powered design and optimization using its proprietary Mexa platform. The second phase will focus on further refinement and validation of the most promising molecules, supported by relevant experimental data.

This collaboration reflects a shared commitment to advancing next-generation modalities and accelerating the discovery of innovative cyclic peptide-based drug candidates through cutting-edge AI-powered design approaches.